.gif)
Mobia Medical, Inc.
27
Recent developments include insider buying activity and mention among top biotech gainers, reflecting some market engagement with the company.
- Insider buying activity involving Mobia Medical was reported on May 12, 2026, indicating potential confidence from company insiders [N2].
- Mobia Medical was mentioned among top biotech gainers on June 17, 2026, suggesting notable market activity or interest in the company during that period [N1].
- The company filed its quarterly 10-Q report on August 11, 2026, disclosing financial results for the quarter ended June 30, 2026 [S1].
Mobia Medical, Inc. is a company with publicly available quarterly financial data as of June 30, 2026. The company reported revenue and net losses for the quarter, alongside a strong liquidity position. Specific details about its sector, industry, and business model are not disclosed in the available data.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Mobia Medical, Inc. reported $13.51 million in revenue and a net loss of $21.04 million for the quarter ended June 30, 2026, with strong liquidity indicated by a current ratio of 13.28 and cash ratio of 12.24 as of that date [S1].
The company maintains a strong liquidity position with substantial cash reserves relative to liabilities, which supports operational flexibility. Insider buying activity and inclusion in biotech gainers lists suggest some positive market interest.
Mobia Medical reported a net loss for the quarter, indicating ongoing profitability challenges. The lack of disclosed sector and industry information limits clarity on business model sustainability and competitive positioning.
No specific information is available regarding Mobia Medical's competitive advantages or moat characteristics in the disclosed data or recent news.
• Profitability Risk: The company reported a net loss of $21.04 million for the quarter ended June 30, 2026, indicating ongoing challenges in achieving profitability.
• Information Transparency Risk: Limited disclosure of sector, industry, and detailed business model information restricts comprehensive analysis and understanding of the company's operations and market positioning.
Business trends: The company reports ongoing net losses alongside modest revenue and maintains strong liquidity ratios.
Execution milestones: Quarterly SEC filings provide transparency on financials; insider buying and market mentions indicate some investor engagement.
Key risks: Profitability challenges and limited disclosure of business model and industry details constrain comprehensive visibility.
Low visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Mobia Medical, Inc. reported financial results for the quarter ended June 30, 2026, in a 10-Q filing dated August 11, 2026.
- As of June 30, 2026, Mobia Medical had cash and cash equivalents of $177.09 million and current assets of $192.15 million, with current liabilities of $14.47 million, resulting in a current ratio of 13.28 and a cash ratio of 12.24, indicating strong liquidity.
- For the quarter ended June 30, 2026, the company reported revenue of $13.51 million and a net loss of $21.04 million, with basic and diluted EPS of -$1.10 per share.
- Recent news includes insider buying activity reported on May 12, 2026, and mention among top biotech gainers on June 17, 2026, indicating some market interest and activity around the company [N2][N1].
Generated 2026-08-12
- S1 | 2026-08-11 | 10-Q
- N1 | 2026-06-17 | www.nasdaq.com | Top Biotech Gainers: CRVO On Watch, SLP Scooped Up, LNAI Back In Compliance, NTHI Advances NEO212 | https://www.nasdaq.com/articles/top-biotech-gainers-crvo-watch-slp-scooped-lnai-back-compliance-nthi-advances-neo212
- N2 | 2026-05-12 | www.nasdaq.com | Tuesday 5/12 Insider Buying Report: WGS, MOBI | https://www.nasdaq.com/articles/tuesday-5-12-insider-buying-report-wgs-mobi
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.
Generated by Valye SEC Pipeline Engine